Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2001 Nov;56(11):888–890. doi: 10.1136/thorax.56.11.888

New insights into the pathogenesis and treatment of primary pulmonary hypertension

N Rudarakanchana 1, R Trembath 1, N Morrell 1
PMCID: PMC1745964  PMID: 11641516

Full Text

The Full Text of this article is available as a PDF (87.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 Aug 29;335(9):609–616. doi: 10.1056/NEJM199608293350901. [DOI] [PubMed] [Google Scholar]
  2. Deng Z., Morse J. H., Slager S. L., Cuervo N., Moore K. J., Venetos G., Kalachikov S., Cayanis E., Fischer S. G., Barst R. J. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000 Jul 20;67(3):737–744. doi: 10.1086/303059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dorai H., Vukicevic S., Sampath T. K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol. 2000 Jul;184(1):37–45. doi: 10.1002/(SICI)1097-4652(200007)184:1<37::AID-JCP4>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  4. Gaine S. P., Rubin L. J. Primary pulmonary hypertension. Lancet. 1998 Aug 29;352(9129):719–725. doi: 10.1016/S0140-6736(98)02111-4. [DOI] [PubMed] [Google Scholar]
  5. Grünig E., Janssen B., Mereles D., Barth U., Borst M. M., Vogt I. R., Fischer C., Olschewski H., Kuecherer H. F., Kübler W. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation. 2000 Sep 5;102(10):1145–1150. doi: 10.1161/01.cir.102.10.1145. [DOI] [PubMed] [Google Scholar]
  6. Ishida W., Hamamoto T., Kusanagi K., Yagi K., Kawabata M., Takehara K., Sampath T. K., Kato M., Miyazono K. Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J Biol Chem. 2000 Mar 3;275(9):6075–6079. doi: 10.1074/jbc.275.9.6075. [DOI] [PubMed] [Google Scholar]
  7. Kawabata M., Imamura T., Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 1998 Mar;9(1):49–61. doi: 10.1016/s1359-6101(97)00036-1. [DOI] [PubMed] [Google Scholar]
  8. Lee S. D., Shroyer K. R., Markham N. E., Cool C. D., Voelkel N. F., Tuder R. M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998 Mar 1;101(5):927–934. doi: 10.1172/JCI1910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. MacLean M. R., Herve P., Eddahibi S., Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol. 2000 Sep;131(2):161–168. doi: 10.1038/sj.bjp.0703570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Machado R. D., Pauciulo M. W., Thomson J. R., Lane K. B., Morgan N. V., Wheeler L., Phillips J. A., 3rd, Newman J., Williams D., Galiè N. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2000 Dec 12;68(1):92–102. doi: 10.1086/316947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Massagué J., Blain S. W., Lo R. S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000 Oct 13;103(2):295–309. doi: 10.1016/s0092-8674(00)00121-5. [DOI] [PubMed] [Google Scholar]
  12. Massagué J., Chen Y. G. Controlling TGF-beta signaling. Genes Dev. 2000 Mar 15;14(6):627–644. [PubMed] [Google Scholar]
  13. Miyazono K. TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):15–22. doi: 10.1016/s1359-6101(99)00025-8. [DOI] [PubMed] [Google Scholar]
  14. Morrell N. W., Yang X., Upton P. D., Jourdan K. B., Morgan N., Sheares K. K., Trembath R. C. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 2001 Aug 14;104(7):790–795. doi: 10.1161/hc3201.094152. [DOI] [PubMed] [Google Scholar]
  15. Nakaoka T., Gonda K., Ogita T., Otawara-Hamamoto Y., Okabe F., Kira Y., Harii K., Miyazono K., Takuwa Y., Fujita T. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest. 1997 Dec 1;100(11):2824–2832. doi: 10.1172/JCI119830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Newman J. H., Lane K. B. Hypertensive pulmonary vascular disease: dawn of the age of prevention? Am J Respir Crit Care Med. 2000 Dec;162(6):2020–2021. doi: 10.1164/ajrccm.162.6.ed12-00c. [DOI] [PubMed] [Google Scholar]
  17. Orte C., Polak J. M., Haworth S. G., Yacoub M. H., Morrell N. W. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol. 2000 Nov;192(3):379–384. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  18. Rubin L. J. Primary pulmonary hypertension. N Engl J Med. 1997 Jan 9;336(2):111–117. doi: 10.1056/NEJM199701093360207. [DOI] [PubMed] [Google Scholar]
  19. Sakou T. Bone morphogenetic proteins: from basic studies to clinical approaches. Bone. 1998 Jun;22(6):591–603. doi: 10.1016/s8756-3282(98)00053-2. [DOI] [PubMed] [Google Scholar]
  20. Schulick A. H., Taylor A. J., Zuo W., Qiu C. B., Dong G., Woodward R. N., Agah R., Roberts A. B., Virmani R., Dichek D. A. Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6983–6988. doi: 10.1073/pnas.95.12.6983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shovlin C. L., Hughes J. M., Scott J., Seidman C. E., Seidman J. G. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet. 1997 Jul;61(1):68–79. doi: 10.1086/513906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sirard C., Kim S., Mirtsos C., Tadich P., Hoodless P. A., Itié A., Maxson R., Wrana J. L., Mak T. W. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling. J Biol Chem. 2000 Jan 21;275(3):2063–2070. doi: 10.1074/jbc.275.3.2063. [DOI] [PubMed] [Google Scholar]
  23. Smith P., Heath D., Yacoub M., Madden B., Caslin A., Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol. 1990 Feb;160(2):111–121. doi: 10.1002/path.1711600204. [DOI] [PubMed] [Google Scholar]
  24. Thomson J. R., Machado R. D., Pauciulo M. W., Morgan N. V., Humbert M., Elliott G. C., Ward K., Yacoub M., Mikhail G., Rogers P. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000 Oct;37(10):741–745. doi: 10.1136/jmg.37.10.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Trembath R. C., Thomson J. R., Machado R. D., Morgan N. V., Atkinson C., Winship I., Simonneau G., Galie N., Loyd J. E., Humbert M. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001 Aug 2;345(5):325–334. doi: 10.1056/NEJM200108023450503. [DOI] [PubMed] [Google Scholar]
  26. Tuder R. M., Groves B., Badesch D. B., Voelkel N. F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994 Feb;144(2):275–285. [PMC free article] [PubMed] [Google Scholar]
  27. Yi E. S., Kim H., Ahn H., Strother J., Morris T., Masliah E., Hansen L. A., Park K., Friedman P. J. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1577–1586. doi: 10.1164/ajrccm.162.4.9912131. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES